Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of the Combination of Bevacizumab, Everolimus and LBH589 (BEL) for the Treatment of Advanced Solid Tumors

NCT01055795 is registered in ClinicalTrials.gov with Herbert Hurwitz as lead sponsor.

NCT NCT01055795
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01055795 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of the Combination of Bevacizumab, Everolimus and LBH589 (BEL) for the Treatment of Advanced Solid Tumors
Lead sponsor
Herbert Hurwitz
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2010
Completion date
May 31, 2012
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors